Chapter

Pharmacological augmentation strategies for depression

Roger S. McIntyre and Jay Nathanson

in Severe Depression

Published on behalf of Oxford University Press

Published in print February 2010 | ISBN: 9780199570249
Published online May 2011 | e-ISBN: 9780191740350 | DOI: https://dx.doi.org/10.1093/med/9780199570249.003.0008

Series: Oxford Psychiatry Library

Pharmacological augmentation strategies for depression

Show Summary Details

Preview

The best proven augmentation strategy in MDD is with the use of second-generation antipsychotics (SGAs, “atypicals”)

Several SGAs have received US FDA approval for the treatment of MDD when antidepressant monotherapy is insufficient and/or in treatment resistant populations, but there are likely efficacy differences across SGAs.

Available evidence suggests that SGAs offer a robust antidepressant effect in individuals with severe phenotypes of MDD.

Chapter.  1779 words. 

Subjects: Psychiatry

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content. subscribe or login to access all content.